MIRVASO 3 mg/g, gel tube, 30 g
Active ingredients: Brimonidine, Brimonidine tartrate
Commercialized according to BDPMDispensing in France: Prescription only
Geltube, 30 gcutanée
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- MIRVASO 3 mg/g, gel
- Pharmaceutical form
- gel
- Route of administration
- cutanée
- Presentation description
- 1 tube(s) polyéthylène EAA : éthylène acrylique acide aluminium avec fermeture de sécurité enfant de 30 g
- Marketing authorisation holder
- GALDERMA, THE NETHERLANDS BRANCH (PAYS-BAS)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 11 Jan 2016
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68293613CIP72802778CIP133400928027788Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| BRIMONIDINEgel | 3,3 mg · 1 g de gel | FT |
| TARTRATE DE BRIMONIDINEgel | 5 mg · 1 g de gel | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.